StreetInsider.com News Articles

Form 8-K ELI LILLY & Co For: Oct 29

Thu, 29 Oct 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20261029/27252511.html

Eli Lilly jumps on earnings beat, raised guidance

Thu, 29 Oct 2026 07:01:32 -0400

Investing.com -- Eli Lilly and Company (NYSE: LLY) shares are over 4% higher premarket after the company reported third-quarter results that exceeded analyst expectations and raised its full-year guidance, driven by strong demand for its diabetes and weight-loss treatments Mounjaro and Zepbound.

The pharmaceutical company posted adjusted earnings per share of $7.48, beating the analyst consensus of $5.60 by $1.88. Revenue reached $24.4 billion, up 39% YoY from $17.6 billion in the third quarter of 2025, and surpassing the consensus estimate of $22.42 billion. Third-quarter revenue included approximately $900 million in benefits, primarily from $410 million in Jardiance milestones

Eli Lilly jumps on earnings beat, raised guidance

Thu, 29 Oct 2026 07:01:32 -0400

Eli Lilly & Co. (LLY) Tops Q3 EPS by $1.88, Beats on Revenue; Offers FY26 Guidance

Thu, 29 Oct 2026 06:48:41 -0400

Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $7.48, $1.88 better than the analyst estimate of $5.60. Revenue for the quarter came in at $24.4 billion versus the consensus estimate of $22.42 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2026 EPS of $35.00-$36.00, versus the consensus of $34.46. Eli Lilly & Co. sees FY2026 revenue of $91-92 billion, versus the consensus of $88.7 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

Eli Lilly & Co. (LLY) Tops Q3 EPS by $1.88, Beats on Revenue; Offers FY26 Guidance

Thu, 29 Oct 2026 06:48:41 -0400

GUIDANCE:

Eli Lilly & Co. sees FY2026 EPS of $35.00-$36.00, versus the consensus of $34.46. Eli Lilly & Co. sees FY2026 revenue of $91-92 billion, versus the consensus of $88.7 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Thu, 29 Oct 2026 06:45:00 -0400

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound.
Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.

Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

Thu, 29 Oct 2026 06:45:00 -0400

Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound.
Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance milestones (no further milestones remain) and favorable adjustments to rebate and discount estimates.

Eli Lilly Q3 earnings preview: profit weak, revenue to rise on Mounjaro strength

Thu, 29 Oct 2026 02:00:00 -0400

Investing.com-- Eli Lilly is set to report its third-quarter earnings before the market open on Thursday, Oct 29, with estimates pointing to a softer profit and stronger revenue on overseas sales of its Mounjaro weight loss medication.

Lilly is expected to post earning per share of $5.60 on revenue of $22.42 billion for the three months to September 30, Investing.com forecasts showed.

That compares to EPS of $7.02 and revenue of $17.60 billion from a year earlier.

Goldman Sachs analysts said they expect revenue to beat consensus at $23.1 billion, fueled chiefly by strong sales of Mounjaro outside the United States.

Eli Lilly Q3 earnings preview: profit weak, revenue to rise on Mounjaro strength

Thu, 29 Oct 2026 02:00:00 -0400

Lilly is expected to post earning per share of $5.60 on revenue of $22.42 billion for the three months to September 30, Investing.com forecasts showed.

That compares to EPS of $7.02 and revenue of $17.60 billion from a year earlier.

Goldman Sachs analysts said they expect revenue to beat consensus at $23.1 billion, fueled chiefly by strong sales of Mounjaro outside the United States.

Eli Lilly Q3 earnings preview: profit weak, revenue to rise on Mounjaro strength

Thu, 29 Oct 2026 02:00:00 -0400

Lilly is expected to post earning per share of $5.60 on revenue of $22.42 billion for the three months to September 30, Investing.com forecasts showed.

That compares to EPS of $7.02 and revenue of $17.60 billion from a year earlier.

Goldman Sachs analysts said they expect revenue to beat consensus at $23.1 billion, fueled chiefly by strong sales of Mounjaro outside the United States.

Eli Lilly & Co. (LLY) call put ratio 1 call to 2 puts into the expected release of quarter results

Wed, 28 Oct 2026 10:31:41 -0400

Eli Lilly & Co. (NYSE: LLY) 30 weekly call option implied volatility is at 108, November is at 47; compared to its 52-week average of 28 to 49. Call put ratio 1 call to 2 puts into the expected release of quarter results before the bell on October 29.

Eli Lilly & Co. (LLY) call put ratio 1 call to 2 puts into the expected release of quarter results

Wed, 28 Oct 2026 10:31:41 -0400

Lilly's retatrutide outperforms Ozempic in phase 3 diabetes trial

Wed, 28 Oct 2026 06:45:30 -0400

Eli Lilly and Company (NYSE: LLY) reported that its investigational drug retatrutide reduced blood sugar and body weight more than Ozempic 2 mg in a Phase 3 head-to-head clinical trial involving adults with type 2 diabetes.

The TRANSCEND-T2D-2 trial, which enrolled 1,298 participants over 80 weeks, showed that both doses of retatrutide (9 mg and 12 mg) reduced A1C by an average of 2.2 percentage points, compared with 1.8 percentage points for Ozempic 2 mg. Participants started with an average baseline A1C of 8.3%.

On body weight, participants taking retatrutide 9 mg lost an average of 44.3 lbs (19.5%), and those on

Lilly's retatrutide outperforms Ozempic in phase 3 diabetes trial

Wed, 28 Oct 2026 06:45:30 -0400

On body weight, participants taking retatrutide 9 mg lost an average of 44.3 lbs (19.5%), and those on

Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

Wed, 28 Oct 2026 06:45:00 -0400

In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks

Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeks

TRANSCEND-T2D-2

Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

Wed, 28 Oct 2026 06:45:00 -0400

In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks

Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeks

TRANSCEND-T2D-2

Eli Lilly names Ilya Yuffa to lead new global markets unit

Tue, 27 Oct 2026 16:03:33 -0400

Eli Lilly and Company (NYSE: LLY) announced that Patrik Jonsson, executive vice president and president of Lilly International, will retire at the end of 2026 after a 36-year career with the company.
Effective Jan. 1, 2027, Lilly will consolidate its U.S. and international businesses into a single unit called Lilly Global Markets. Ilya Yuffa will assume the role of executive vice president and president of the new division, overseeing customer strategy and execution worldwide.
Jonsson joined Lilly in 1990 as a sales representative in Sweden. Over his career he led Lilly operations in Sweden, Scandinavia, Italy, and Japan, and held executive roles

Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets

Tue, 27 Oct 2026 16:03:00 -0400

Yuffa will take on an expanded role as the company scales for its next phase of growth

Key highlights:

Patrik Jonsson, executive vice president and president, Lilly International, has decided to retire at

Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets

Tue, 27 Oct 2026 16:03:00 -0400

Yuffa will take on an expanded role as the company scales for its next phase of growth

Key highlights:

Patrik Jonsson, executive vice president and president, Lilly International, has decided to retire at

Eli Lilly & Co. (LLY) call put ratio 1 call to 1.8 puts into quarter results

Tue, 27 Oct 2026 11:07:10 -0400

Eli Lilly & Co. (NYSE: LLY) October 30 weekly call option implied volatility is at 90, November is at 47; compared to its 52-week average of 28 to 49. Call put ratio 1 call to 1.8 puts into the expected release of quarter results before the bell on October 29.

Eli Lilly & Co. (LLY) call put ratio 1 call to 1.8 puts into quarter results

Tue, 27 Oct 2026 11:07:10 -0400

Eli Lilly & Co. (NYSE: LLY) October 30 weekly call option implied volatility is at 90, November is at 47; compared to its 52-week average of 28 to 49. Call put ratio 1 call to 1.8 puts into the expected release of quarter results before the bell on October 29.

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

Mon, 26 Oct 2026 13:12:25 -0400

Four U.S. Manufacturing Projects Total $17.1 Billion as Drugmakers Prepare for Expanding Demand
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity. The investments raise a larger question: could managing obesity generate trillions of dollars in drug sales over the next two decades?

Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030,

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

Mon, 26 Oct 2026 13:12:25 -0400

Four U.S. Manufacturing Projects Total $17.1 Billion as Drugmakers Prepare for Expanding Demand
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity. The investments raise a larger question: could managing obesity generate trillions of dollars in drug sales over the next two decades?

Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030,

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

Mon, 26 Oct 2026 13:12:25 -0400

Four U.S. Manufacturing Projects Total $17.1 Billion as Drugmakers Prepare for Expanding Demand
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity. The investments raise a larger question: could managing obesity generate trillions of dollars in drug sales over the next two decades?

Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030,

Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

Mon, 26 Oct 2026 13:12:25 -0400

Four U.S. Manufacturing Projects Total $17.1 Billion as Drugmakers Prepare for Expanding Demand
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of dollars to new manufacturing facilities as obesity medicines become a major commercial opportunity. The investments raise a larger question: could managing obesity generate trillions of dollars in drug sales over the next two decades?

Goldman Sachs Research forecasts global obesity-drug sales of $114 billion annually by 2030,